地理萎缩的治疗创新：前景光明。

IF 4 3区医学 Q1 PHARMACOLOGY & PHARMACY

Current Opinion in Pharmacology Pub Date : 2024-09-06 DOI:10.1016/j.coph.2024.102484

Eva C. de Oliveira Figueiredo , Claudio Bucolo , Chiara M. Eandi

{"title":"地理萎缩的治疗创新：前景光明。","authors":"Eva C. de Oliveira Figueiredo , Claudio Bucolo , Chiara M. Eandi","doi":"10.1016/j.coph.2024.102484","DOIUrl":null,"url":null,"abstract":"<div><p>This mini review spotlights the most promising treatments for geographic atrophy, the advanced form of age-related macular degeneration, often resulting in severe and irreversible vision loss. The pathophysiology is complex, and various therapeutic strategies, including anticomplement therapies, gene therapies, cell-based interventions, and artificial intelligence–driven diagnostics are discussed.</p><p>Anticomplement therapies (antifactors C3 and C5) showed promise in reducing the inflammatory response and the progression of the atrophy. Gene therapies, targeting specific genetic mutations, are under development to correct underlying defects and potentially reverse disease progression. Cell-based therapies are gaining momentum, with early studies indicating encouraging results in the replacement of damaged retinal pigment epithelium cells.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"78 ","pages":"Article 102484"},"PeriodicalIF":4.0000,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1471489224000547/pdfft?md5=df5b4fff4283445369fb45638e495d89&pid=1-s2.0-S1471489224000547-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Therapeutic innovations for geographic atrophy: A promising horizon\",\"authors\":\"Eva C. de Oliveira Figueiredo , Claudio Bucolo , Chiara M. Eandi\",\"doi\":\"10.1016/j.coph.2024.102484\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>This mini review spotlights the most promising treatments for geographic atrophy, the advanced form of age-related macular degeneration, often resulting in severe and irreversible vision loss. The pathophysiology is complex, and various therapeutic strategies, including anticomplement therapies, gene therapies, cell-based interventions, and artificial intelligence–driven diagnostics are discussed.</p><p>Anticomplement therapies (antifactors C3 and C5) showed promise in reducing the inflammatory response and the progression of the atrophy. Gene therapies, targeting specific genetic mutations, are under development to correct underlying defects and potentially reverse disease progression. Cell-based therapies are gaining momentum, with early studies indicating encouraging results in the replacement of damaged retinal pigment epithelium cells.</p></div>\",\"PeriodicalId\":50603,\"journal\":{\"name\":\"Current Opinion in Pharmacology\",\"volume\":\"78 \",\"pages\":\"Article 102484\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2024-09-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1471489224000547/pdfft?md5=df5b4fff4283445369fb45638e495d89&pid=1-s2.0-S1471489224000547-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1471489224000547\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1471489224000547","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

地理萎缩是老年性黄斑变性的晚期形式，通常会导致严重和不可逆的视力丧失。病理生理学非常复杂，本文将讨论各种治疗策略，包括抗互补疗法、基因疗法、细胞干预和人工智能诊断。抗互补疗法（抗原 C3 和 C5）在减轻炎症反应和减少萎缩进展方面显示出前景。目前正在开发针对特定基因突变的基因疗法，以纠正潜在的缺陷，并有可能逆转疾病的进展。以细胞为基础的疗法势头正劲，早期研究表明，在替换受损视网膜色素上皮细胞方面取得了令人鼓舞的成果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Therapeutic innovations for geographic atrophy: A promising horizon

This mini review spotlights the most promising treatments for geographic atrophy, the advanced form of age-related macular degeneration, often resulting in severe and irreversible vision loss. The pathophysiology is complex, and various therapeutic strategies, including anticomplement therapies, gene therapies, cell-based interventions, and artificial intelligence–driven diagnostics are discussed.

Anticomplement therapies (antifactors C3 and C5) showed promise in reducing the inflammatory response and the progression of the atrophy. Gene therapies, targeting specific genetic mutations, are under development to correct underlying defects and potentially reverse disease progression. Cell-based therapies are gaining momentum, with early studies indicating encouraging results in the replacement of damaged retinal pigment epithelium cells.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Opinion in Pharmacology 医学-药学

CiteScore

8.80

自引率

2.50%

发文量

131

审稿时长

4-8 weeks

期刊介绍： Current Opinion in Pharmacology (COPHAR) publishes authoritative, comprehensive, and systematic reviews. COPHAR helps specialists keep up to date with a clear and readable synthesis on current advances in pharmacology and drug discovery. Expert authors annotate the most interesting papers from the expanding volume of information published today, saving valuable time and giving the reader insight on areas of importance.